Replies to post #2391 on Idenix Pharmaceuticals (IDIX)

[ThomasS]

Didn't anyone find this blurb important, in the positive sense?

"Efavirenz appeared to be active against IDX899 resistant viruses and IDX899 remained active against efavirenz-resistant virus containing as many as four NNRTI-resistance mutations. "

[palindromy]

How does the efficacy profile compare with that of Sustiva given the limited info available so far?
I find it surprising that the company started with a high dose and is going lower, I thought it was more typical to start off with the lower doses.

[DewDiligence]

IDX899 update from IDIX CC:

The 400mg dosing cohort has now been completed and the reduction in viral load was in the 1.5-2-log range, which is about as good as one can get in a short HIV study (#msg-27349650).

Because the requisite potency was seen at 400mg, dosing in the 200mg cohort has begun. If 200mg shows sufficient potency, a 100mg dose may also be tested.

IDIX’s reasons for testing lower and lower doses are set forth in #msg-26800695.

There have been zero patient discontinuations to date in any of the dosing cohorts.